CN118384143A - 用于治疗炎症性病症的化合物和方法 - Google Patents

用于治疗炎症性病症的化合物和方法 Download PDF

Info

Publication number
CN118384143A
CN118384143A CN202410485765.2A CN202410485765A CN118384143A CN 118384143 A CN118384143 A CN 118384143A CN 202410485765 A CN202410485765 A CN 202410485765A CN 118384143 A CN118384143 A CN 118384143A
Authority
CN
China
Prior art keywords
compound
administered
compounds
doi
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410485765.2A
Other languages
English (en)
Chinese (zh)
Inventor
C·D·尼克尔斯
G·比拉克
D·E·尼克尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Luis Anna State University Monitoring Committee College Of Agriculture And Mechanical Engineering
Original Assignee
Luis Anna State University Monitoring Committee College Of Agriculture And Mechanical Engineering
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luis Anna State University Monitoring Committee College Of Agriculture And Mechanical Engineering filed Critical Luis Anna State University Monitoring Committee College Of Agriculture And Mechanical Engineering
Publication of CN118384143A publication Critical patent/CN118384143A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202410485765.2A 2019-04-12 2020-04-13 用于治疗炎症性病症的化合物和方法 Pending CN118384143A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962833140P 2019-04-12 2019-04-12
US62/833,140 2019-04-12
CN202080030668.4A CN113784709B (zh) 2019-04-12 2020-04-13 用于治疗炎症性病症的化合物和方法
PCT/US2020/027981 WO2020210823A1 (en) 2019-04-12 2020-04-13 Compounds and methods for treating inflammatory disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080030668.4A Division CN113784709B (zh) 2019-04-12 2020-04-13 用于治疗炎症性病症的化合物和方法

Publications (1)

Publication Number Publication Date
CN118384143A true CN118384143A (zh) 2024-07-26

Family

ID=72751451

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410485765.2A Pending CN118384143A (zh) 2019-04-12 2020-04-13 用于治疗炎症性病症的化合物和方法
CN202080030668.4A Active CN113784709B (zh) 2019-04-12 2020-04-13 用于治疗炎症性病症的化合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080030668.4A Active CN113784709B (zh) 2019-04-12 2020-04-13 用于治疗炎症性病症的化合物和方法

Country Status (9)

Country Link
US (2) US12398093B2 (cg-RX-API-DMAC7.html)
EP (2) EP4685135A3 (cg-RX-API-DMAC7.html)
JP (1) JP7596296B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220008264A (cg-RX-API-DMAC7.html)
CN (2) CN118384143A (cg-RX-API-DMAC7.html)
AU (1) AU2020271915B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020424A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136153A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020210823A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024528031A (ja) * 2021-07-26 2024-07-26 ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュアル アンド メカニカル カレッジ 5-ht2応答性状態を治療するための化合物及び方法
SE2151519A1 (en) 2021-12-10 2023-06-11 Amidea Sweden Ab 2-(2,5-dimethoxyphenyl)ethanamine and uses thereof
WO2024010765A1 (en) * 2022-07-05 2024-01-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions for treating 5-ht2 conditions and methods of using the same
WO2024191924A2 (en) * 2023-03-10 2024-09-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods of use thereof
WO2025240982A1 (en) 2024-05-17 2025-11-20 2A Biosciences, Inc. 5-alkoxymethyl and 5-hydroxymethyl phenethylamines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877802B2 (en) * 2005-07-28 2014-11-04 Duke Univerity Antiparkinsonian action of phenylisopropylamines
US9642819B2 (en) * 2008-07-10 2017-05-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Low dosage serotonin 5-HT2A receptor agonist to suppress inflammation
EA035868B1 (ru) * 2012-08-17 2020-08-24 Смартек Интернэшнл Эл-Эл-Си Приготовление высушенных липосом для применения в системах выпуска в прессованном виде
US20200078335A1 (en) 2017-05-01 2020-03-12 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods to reduce pathogenesis
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
JP7596296B2 (ja) 2024-12-09
AU2020271915B2 (en) 2025-10-09
CN113784709A (zh) 2021-12-10
US20260070872A1 (en) 2026-03-12
JP2022527401A (ja) 2022-06-01
AU2020271915A1 (en) 2021-11-04
US20220119340A1 (en) 2022-04-21
CA3136153A1 (en) 2020-10-15
EP3952851B1 (en) 2025-12-03
EP4685135A3 (en) 2026-04-15
EP3952851A1 (en) 2022-02-16
KR20220008264A (ko) 2022-01-20
EP4685135A2 (en) 2026-01-28
US12398093B2 (en) 2025-08-26
WO2020210823A1 (en) 2020-10-15
EP3952851A4 (en) 2023-01-11
BR112021020424A2 (pt) 2021-12-21
CN113784709B (zh) 2024-05-10

Similar Documents

Publication Publication Date Title
AU2020271915B2 (en) Compounds and methods for treating inflammatory disorders
JP5196701B2 (ja) クロモリンナトリウムの経口投与用製剤
EP1807083B1 (en) Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
AU2011287711B2 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
JPH09507216A (ja) 5−(2−イミダゾリニルアミノ)ベンゾイミダゾール誘導体、それらの製法及びα−2−アドレノセプター作動剤としてのそれらの用途
KR20090129414A (ko) 인플루엔자 치료제
EA037447B1 (ru) Способ лечения эозинофильных заболеваний
JPH09506622A (ja) α−2−アドレノセプター作動剤として有用な6−(2−イミダゾリニルアミノ)キノキサリン化合物
JPH09507219A (ja) α−2−アドレノセプター作動剤として有用な7−(2−イミダゾリニルアミノ)キノリン化合物
CN107438613B (zh) 用于预防或治疗感觉毛细胞死亡的化合物和方法
JP2650756B2 (ja) 皮膚および粘膜上皮の疾患の治療のための4‐キノリンカルボン酸誘導体
WO2022197885A1 (en) Compositions and methods for treating neurologic diseases
US20240067604A1 (en) Combinations of irs/stat3 dual modulators and anti pd-1/pd-l1 antibodies for treating cancer
TW200848035A (en) New combination 627
JPH09511483A (ja) α−2−アドレノセプター作動剤として有用な6−(2−イミダゾリニルアミノ)キノリン化合物
US20090093415A1 (en) Therapeutic agent for irritable bowel syndrome
CN110582278B (zh) 药物组合物及其用途
JP2001500526A (ja) 粘液溶解剤としての2−メチル−チアゾリジン−2,4−ジカルボン酸の使用
HK40056643A (en) Compounds and methods for treating inflammatory disorders
KR102553153B1 (ko) 포유류에서 질환을 치료하기 위한 신규한 다중표적 약물
HK40096678A (en) Pharmaceutical composition for preventing or treating fibrosis
JPWO2004087148A1 (ja) 肺疾患の治療および/または予防剤
JPH04506517A (ja) 3,3―ジ置換インドリンの鼻腔内投与
JPWO2005011674A1 (ja) 気管支喘息の予防及び/または治療剤
WO2002034251A1 (en) Treatment of asthma with lfm analogues

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination